Switching transplant drug may cut skin cancer risk
NCT ID NCT00133887
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at kidney transplant patients who already had one skin cancer. It compared switching their anti-rejection medicine to rapamycin versus staying on standard drugs. The goal was to see if rapamycin could prevent new skin cancers over two years while keeping the transplanted kidney healthy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KIDNEY TRANSPLANTATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hôpital Edouard Herriot - Service de Dermatologie
Lyon, 69003, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can your genes predict your melanoma risk?
- AI may spot hidden kidney transplant rejection
- A drug given to organ donors may help kidneys work faster after transplant
- A UV photo and a cheek swab may be the keys to stopping sunburn before it starts
- Which diuretic protects a new kidney best? a Head-to-Head trial puts furosemide and mannitol to the test
- Blood test clues could make antifungal dosing safer for transplant patients